FDA Approves SAPIEN 3 Platform for Asymptomatic Severe Aortic Stenosis

MONDAY, May 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved the SAPIEN 3 platform, a transcatheter aortic valve replacement (TAVR) therapy, for patients with severe aortic stenosis without symptoms. The approval is the first for TAVR in asymptomatic patients.In the EARLY TAVR trial, which informed the approval, patients with asymptomatic severe aortic stenosis were randomly assigned to either TAVR or watchful waiting. During a median follow-up of 3.8 years, 26.8 percent of the 455 patients in the TAVR group experienced death, stroke, or unplanned cardiovascular hospitalization compared with 45.3 percent of the 446 patients in the clinical surveillance group."There is an urgent need to change practice and TAVR guidelines for the treatment of aortic stenosis patients, which currently recommend 'watchful waiting' until symptoms develop," Philippe Genereux, M.D., from the Gagnon Cardiovascular Institute at Morristown Medical Center in New Jersey, said in a statement. "As we saw in the EARLY TAVR trial, patients originally designated as asymptomatic became symptomatic in sudden and unpredictable ways, underscoring the importance of early evaluation by a heart team to improve patient outcomes and benefit the health care system."Approval of the SAPIEN 3 platform was granted to Edwards Lifesciences.More Information.Sign up for our weekly HealthDay newsletter

FDA Approves SAPIEN 3 Platform for Asymptomatic Severe Aortic Stenosis

Related Stories

Misconceptions About Pelvic Prolapse: A Condition That Effects Millions of Women

Mind-Controlled Bionic Suit Lets Paralyzed Patients Feel Every Step

AI Reveals Negative Labels in Medical Records for Sickle Cell Patients

ACC: Percutaneous Coronary Intervention Can Be Delayed Until After TAVR in Some Patients